These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 21628400)

  • 1. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now.
    Hsieh MM; Fitzhugh CD; Tisdale JF
    Blood; 2011 Aug; 118(5):1197-207. PubMed ID: 21628400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
    Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
    JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.
    Guilcher GMT; Truong TH; Saraf SL; Joseph JJ; Rondelli D; Hsieh MM
    Semin Hematol; 2018 Apr; 55(2):87-93. PubMed ID: 29958564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
    Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
    Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic stem cell transplantation for sickle cell disease: state of the science.
    Talano JA; Cairo MS
    Eur J Haematol; 2015 May; 94(5):391-9. PubMed ID: 25200500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation.
    Kean LS; Durham MM; Adams AB; Hsu LL; Perry JR; Dillehay D; Pearson TC; Waller EK; Larsen CP; Archer DR
    Blood; 2002 Mar; 99(5):1840-9. PubMed ID: 11861303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative donor: αß/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease.
    Foell J; Kleinschmidt K; Jakob M; Troeger A; Corbacioglu S
    Hematol Oncol Stem Cell Ther; 2020 Jun; 13(2):98-105. PubMed ID: 32202248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
    Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
    Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic stem cell transplantation for sickle cell disease: The changing landscape.
    Kassim AA; Sharma D
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):259-266. PubMed ID: 28641096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic cellular gene therapy for hemoglobinopathies.
    Gaziev J; Lucarelli G
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1145-63. PubMed ID: 21075285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease.
    Devadasan D; Sun CW; Westin ER; Wu LC; Pawlik KM; Townes TM; Goldman FD
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1554-1562. PubMed ID: 29684562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.
    Hwang YY; Mohty M; Chim CS
    Hematology; 2015 Mar; 20(2):61-71. PubMed ID: 24993587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.
    Hsieh MM; Kang EM; Fitzhugh CD; Link MB; Bolan CD; Kurlander R; Childs RW; Rodgers GP; Powell JD; Tisdale JF
    N Engl J Med; 2009 Dec; 361(24):2309-17. PubMed ID: 20007560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogenic hematopoietic stem cell transplantation in sickle cell disease.
    Furstenau DK; Tisdale JF
    Transfus Apher Sci; 2021 Feb; 60(1):103057. PubMed ID: 33485798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics.
    Horwitz ME; Spasojevic I; Morris A; Telen M; Essell J; Gasparetto C; Sullivan K; Long G; Chute J; Chao N; Rizzieri D
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1422-6. PubMed ID: 18022571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
    Strocchio L; Zecca M; Comoli P; Mina T; Giorgiani G; Giraldi E; Vinti L; Merli P; Regazzi M; Locatelli F
    Br J Haematol; 2015 Jun; 169(5):726-36. PubMed ID: 25818248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of allogeneic Hematopoietic Stem Cell Transplantation on Diamond-Blackfan anemia using busulfan-based myeloablative regimen.
    Behfar M; Koochakzadeh L; Yazdanian N; Salajegheh P; Rostami T; Khodayari-Namini N; Ghavamzadeh A; Hamidieh AA
    Turk J Pediatr; 2019; 61(3):407-412. PubMed ID: 31916719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic hematopoietic stem cell transplantation in children with sickle cell disease.
    Locatelli F; Pagliara D
    Pediatr Blood Cancer; 2012 Aug; 59(2):372-6. PubMed ID: 22544533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic/Matched Related Transplantation for β-Thalassemia and Sickle Cell Anemia.
    Bernaudin F; Pondarré C; Galambrun C; Thuret I
    Adv Exp Med Biol; 2017; 1013():89-122. PubMed ID: 29127678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.